Pneumothorax Treatment Market By Product Type (Chest Drainage Systems [Wet Suction Systems, Dry Suction Systems, Portable and Ambulatory Drainage Systems, Digital Chest Drainage Systems], Chest Tubes and Pleural Catheters, Needle Aspiration Devices, Pleurodesis Products, Thoracic Surgical Devices, Accessories and Consumables); By Application (Primary Spontaneous Pneumothorax, Secondary Spontaneous Pneumothorax, Traumatic Pneumothorax, Iatrogenic Pneumothorax, Neonatal Pneumothorax, Postoperative Pneumothorax); By Treatment Type (Conservative Management, Needle Aspiration, Chest-Tube Drainage, Ambulatory Drainage, Chemical Pleurodesis, Surgical Treatment); By End User (Hospitals, Trauma and Emergency Care Centers, Ambulatory Surgical Centers, Specialty Respiratory and Thoracic Clinics, Ambulatory Care Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Pneumothorax Treatment Market: Complex Cases, Ambulatory Care, and Safety Standards Redirect Revenue

The Global Pneumothorax Treatment Market was valued at USD 2.23 billion in 2025 and is projected to reach USD 3.37 billion by 2032, growing at a CAGR of 6.1%, according to Strategic Market Research.

 

Hospital demand remains concentrated in patients who require urgent drainage, surgery, prolonged air-leak management, or treatment for underlying lung disease. Conservative care is reducing routine intervention among selected stable patients, while recurrent and secondary pneumothorax are shifting spending toward surgery, pleurodesis, bronchoscopic treatment, postoperative drainage, and specialist follow-up. Suppliers gain stronger positioning when their products reduce hospital stays, support recurrence prevention, and meet tighter safety and training standards.

 

Rising Secondary Pneumothorax Procedures Increase Treatment Intensity

Japan provides the most recent national surgical activity data available from a non-market-research source. The Japanese Association for Thoracic Surgery recorded 14,719 pneumothorax procedures in 2024, up 2.9% from 14,311 in 2023. Spontaneous pneumothorax accounted for 9,920 procedures in 2024, while secondary pneumothorax accounted for 4,799.

Secondary pneumothorax procedures rose by 11.2% between 2023 and 2024, considerably faster than the 2.9% increase in total pneumothorax procedures. The stronger increase matters commercially because secondary cases are commonly associated with damaged lungs, persistent air leakage, longer admissions, and greater treatment complexity. These patients are less likely to move into conservative or rapid-discharge pathways than otherwise healthy patients with uncomplicated primary spontaneous pneumothorax.

Chronic obstructive pulmonary disease was associated with 3,260 Japanese secondary pneumothorax procedures in 2024, representing 68% of that segment. COPD-associated cases increased by 26.6% from 2,576 in 2023. Hospital mortality among secondary pneumothorax procedures associated with COPD reached 2.4% in 2024, compared with 1.4% in the 2023 survey. The figures support sustained hospital spending on drainage systems, suction equipment, air-leak management, thoracic surgery, intensive monitoring, and postoperative care.

Secondary pneumothorax therefore contributes more revenue per patient than routine observation of a stable primary episode. Older patients and those with COPD, lung cancer, interstitial lung disease, or other structural lung disorders often require multidisciplinary care. Suppliers serving complex drainage and thoracic surgery remain less exposed to conservative-treatment substitution than vendors dependent on standard first-episode drainage.

 

Surgery Captures More Value Through Recurrence Prevention

Video-assisted thoracic surgery accounted for 14,315 of Japan’s 14,719 pneumothorax procedures in 2024, equal to approximately 97.3% of the total. Minimally invasive surgery has consequently become the established procedural route in a major national treatment system rather than a small premium alternative. High surgical penetration supports demand for stapling systems, surgical instruments, reinforcement materials, postoperative drains, and operating-room consumables.

Among the 9,920 spontaneous pneumothorax procedures performed in Japan during 2024, 2,293 involved bullectomy alone. Another 6,950 procedures, or 70%, included additional treatment such as coverage with artificial material or parietal pleurectomy. The corresponding 2023 survey also reported additional recurrence-prevention procedures in 70% of spontaneous pneumothorax operations. Hospitals are therefore directing most surgical spending beyond removal of visible bullae toward measures intended to reduce repeated episodes.

Recurrence-prevention procedures expand the revenue attached to each operation through added materials, longer procedure time, postoperative monitoring, and drainage requirements. Suppliers with products embedded in thoracic surgery workflows benefit more than companies competing only for initial emergency drainage. Surgeon familiarity and hospital contracts also create stronger retention because switching products can require training, protocol changes, and operating-room approval.

The 2026 British Thoracic Society Quality Standard states that patients with recurrent spontaneous pneumothorax should have timely access to specialist review and elective recurrence-prevention treatment where clinically appropriate. The standard also requires access to specialist pleural advice for complex disease. These service expectations support referral pathways that move recurrent patients from repeated emergency treatment into planned thoracic care.

 

Pleurodesis Retains Demand Among Patients Unsuitable for Surgery

Chemical pleurodesis remains commercially relevant for secondary pneumothorax patients who cannot undergo surgery or continue to have air leakage despite drainage. A 2024 phase 2 study of talc slurry pleurodesis reported successful drainage-tube removal within 30 days in 23 of 28 patients, equivalent to 82.1%. The confidence interval ranged from 63.1% to 93.9%, reflecting the small study population, but the result supports continued use in carefully selected intractable secondary cases.

Talc pleurodesis uses established materials rather than a high-priced new drug, which limits product-level pricing power. Commercial spending comes from the complete hospital episode, including drainage, imaging, specialist care, pleurodesis administration, monitoring, and possible repeat treatment. Demand remains strongest among older or medically fragile patients for whom surgery carries greater risk.

Hospitals also retain pleurodesis as a recurrence-management option where thoracic surgical access is limited. Suppliers compete through sterile product consistency, packaging, hospital availability, clinical familiarity, and reliable distribution rather than extensive product differentiation. Increasing numbers of complex secondary cases can raise procedure volume even when prices for individual consumables remain constrained.

 

Persistent Air Leaks Support Higher-Value Bronchoscopic Treatment

Persistent air leaks create a smaller but higher-value treatment segment because they prolong drainage and hospital stays. Endobronchial valves offer a bronchoscopic option for patients whose air leaks do not close with standard care and who may not be suitable for surgery.

A 2024 European multicentre study assessed endobronchial valve treatment in 66 patients with persistent air leakage. Air leaks resolved within 30 days in 40 patients, producing a 60.6% resolution rate. The study reported no procedure-related mortality and a complication rate of 6.1%. COPD was the most common underlying lung disease at 39.4%, followed by lung cancer at 33.3%.

The median interval between pneumothorax and valve placement was 24.5 days, indicating that these products are used after prolonged and resource-intensive treatment rather than at initial presentation. Hospitals can justify higher device spending when valve placement helps end persistent drainage, reduces further inpatient days, or avoids surgery in high-risk patients.

Endobronchial valve suppliers operate in a narrower market than conventional chest-drain manufacturers, but the value per patient is substantially higher. Adoption depends on interventional pulmonology capacity, bronchoscopic expertise, patient selection, and reimbursement. Large referral hospitals are more likely to develop these services than smaller facilities, concentrating revenue within specialist centres.

 

Conservative Care Limits Routine Drainage in Stable Patients

The 2023 British Thoracic Society guideline and subsequent European clinical guidance support conservative management for selected clinically stable patients with primary spontaneous pneumothorax. Treatment decisions are increasingly based on symptoms and physiological stability rather than pneumothorax size alone. Hospitals with reliable follow-up can therefore avoid routine drainage or admission in some uncomplicated cases.

Reduced intervention places pressure on standard drainage volume within the primary spontaneous segment. Manufacturers heavily dependent on routine chest-tube placement face more substitution risk than suppliers serving trauma, secondary pneumothorax, postoperative air leakage, and recurrent disease.

Conservative pathways do not remove healthcare spending. Patients still require imaging, clinical review, discharge instructions, and rapid access to treatment if symptoms worsen. Revenue moves from prolonged inpatient care toward organized outpatient services, specialist pleural clinics, and monitoring rather than disappearing entirely.

England’s spontaneous pneumothorax mortality rate declined to 6.9 per million people in 2023 after reaching 8.1 per million in 2021. The latest national mortality analysis also found that chronic lung disease was present in 81% of recorded in-hospital deaths across the study population. Complex secondary disease therefore remains the main clinical-risk segment even as stable primary cases move toward less invasive care.

 

Ambulatory Services Redirect Spending Away from Bed-Days

The British Thoracic Society’s 2026 Quality Standard contains 16 measurable statements covering pleural care. Patients should be offered ambulatory management where clinically appropriate, while emergency pleural procedures must remain accessible 24 hours a day, seven days a week. The requirements support simultaneous demand for portable outpatient systems and dependable hospital inventory.

Ambulatory treatment changes the economic argument for pneumothorax products. Hospitals do not gain value from portability alone. Products command stronger acceptance when they allow suitable patients to leave the hospital earlier without increasing emergency returns or treatment failure.

Portable drainage systems, one-way valves, small-bore catheters, and digital monitoring products can capture more spending as hospitals expand outpatient pathways. Adoption remains dependent on trained clinicians, follow-up appointments, imaging access, and clear escalation protocols. Facilities without these services will continue to rely more heavily on conventional admission and drainage.

The 2026 quality standard also calls for access to pleural nurse specialists and specialist review for complex cases. Hospital investment may therefore extend beyond equipment to staffing, training, data collection, and service coordination. Suppliers that provide education, implementation support, and reliable replacement stock gain an advantage over vendors competing only on unit price.

 

New Training Standards Raise the Cost of Procedural Compliance

The British Thoracic Society introduced new training standards for pleural procedures in January 2026 after a March 2025 audit identified significant safety concerns across UK services. The standards apply across respiratory, acute, and critical-care specialties and set expectations for demonstrating procedural competence.

Standardized training can support wider adoption of pleural procedures while increasing compliance requirements for hospitals. Products accompanied by clear instructions, simulation resources, procedural education, and competency support can gain preference during evaluations. Hospitals may also consolidate purchases around fewer systems to reduce training variation and simplify safety protocols.

The new standards support demand for ultrasound-guided procedural capability, supervised training, and auditable documentation. Suppliers selling drainage kits without education or post-sale support face a weaker position as hospitals formalize competency requirements.

 

NHS Procurement Expands Supplier Choice but Increases Price Pressure

NHS Supply Chain launched a consolidated suction and drainage framework on September 8, 2025. The contract runs through September 7, 2027, with an option for a further 24-month extension. It includes chest and thoracic drainage systems within a dedicated wound-drainage lot.

The framework includes 41 suppliers, of which 10 are new. Expanded supplier participation gives NHS buyers greater product choice and increases competitive pressure on established chest-drainage vendors. National pricing arrangements, product switching, and consolidated purchasing can limit margins for standardized products.

Portfolio breadth, delivery resilience, clinical support, and compliance documentation become more important when dozens of suppliers compete within one framework. Commodity drainage products remain exposed to price comparison, while differentiated ambulatory and digital systems have more room to defend premium pricing through hospital-flow savings.

A separate Northern Ireland chest-drainage contract concluded in March 2024 with a maximum value of approximately £1.05 million excluding VAT. Three bids were submitted, and the framework covered multiple public health trusts. The contract value was not guaranteed purchasing volume, but it confirms that regional healthcare systems aggregate drainage demand and negotiate through competitive tenders.

 

Safety Notices Influence Contract Retention and Product Switching

The FDA classified a correction involving Atrium Express chest drains as a Class I recall in January 2024. The action covered 251,142 devices distributed in the United States and involved a sterility concern associated with a prepackaged syringe. No injuries or deaths had been reported when the notice was published.

A recall affecting more than a quarter of a million units illustrates the scale of chest-drain distribution and the financial exposure attached to quality failures. Hospitals may review inventory, supplier performance, replacement availability, and alternative products after a serious regulatory action. Large suppliers can absorb corrective-action costs more easily, but widespread events can still weaken customer confidence.

NHS Supply Chain issued a field safety notice in November 2025 affecting six Rocket Medical Seldinger chest-drain products. The manufacturer revised its instructions regarding suturing and stated that supply disruption was not expected. The event placed documentation and user training directly within supplier risk management.

Cardinal Health updated instructions for specified chest-drainage units in January 2026 to clarify that the intended population was adults aged 18 years and older. Rocket Medical issued another notice in March 2026 concerning one lot of a chest and abdominal drain set where a needle may have punctured the catheter wall. NHS Supply Chain found no affected stock and reported no expected impact on supply.

Frequent instruction updates and product alerts increase the value of traceability, customer communication, and rapid inventory replacement. Suppliers with robust post-market systems are better placed to retain institutional contracts than companies offering lower prices without comparable support.

 

Revenue Moves Toward Complex Care and Pathway Support

Asia-Pacific surgical demand is supported by Japan’s 14,719 pneumothorax procedures in 2024 and the faster increase in secondary cases. European revenue is moving toward ambulatory care, standardized training, and centralized procurement under the 2026 BTS standards and the 2025 NHS framework. North American supplier positioning is strongly affected by regulatory compliance and the financial exposure created by large product recalls.

Standard chest-drainage systems will retain recurring emergency and inpatient volume, but centralized contracts will continue to restrict pricing. Faster revenue expansion is more likely in persistent air-leak treatment, recurrence-prevention surgery, ambulatory pathway support, and complex secondary pneumothorax. Suppliers combining dependable emergency stock, procedural training, specialist products, and strong post-market service will capture more value than vendors dependent on undifferentiated drainage hardware.

 

Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 2.23 Billion
Revenue Forecast in 2032	USD 3.37 Billion
Overall Growth Rate	CAGR of 6.1% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By Treatment Type, By End User, By Geography
By Product Type	Chest Drainage Systems, Chest Tubes and Pleural Catheters, Needle Aspiration Devices, Pleurodesis Products, Thoracic Surgical Devices, Accessories and Consumables
By Chest Drainage Systems	Wet Suction Systems, Dry Suction Systems, Portable and Ambulatory Drainage Systems, Digital Chest Drainage Systems
By Application	Primary Spontaneous Pneumothorax, Secondary Spontaneous Pneumothorax, Traumatic Pneumothorax, Iatrogenic Pneumothorax, Neonatal Pneumothorax, Postoperative Pneumothorax
By Treatment Type	Conservative Management, Needle Aspiration, Chest-Tube Drainage, Ambulatory Drainage, Chemical Pleurodesis, Surgical Treatment
By End User	Hospitals, Trauma and Emergency Care Centers, Ambulatory Surgical Centers, Specialty Respiratory and Thoracic Clinics, Ambulatory Care Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, Mexico, UK, Germany, France, Italy, Spain, China, Japan, India, South Korea, Australia, Brazil, Argentina, Saudi Arabia, UAE, South Africa
Market Drivers	Rising emergency and trauma-related pneumothorax cases, wider use of portable and digital chest drainage systems, increasing minimally invasive thoracic procedures, growing neonatal and postoperative respiratory monitoring needs, and stronger hospital focus on faster air-leak detection and shorter inpatient stays
Customization Option	Available upon request